Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews · Common Mental Disorders

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 0 · 0%High 3 · 60%

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Response rate at 3 weeks (primary efficacy outcome) · Adults (aged 18 and over) with acute mania

Valproate showed no clear difference in response rate at endpoint at 3 weeks (primary efficacy outcome) compared with olanzapine (low certainty).

1 finding from 1 review

Valproate for acute mania 2019 · Cochrane Headline outcomes only
OR 0.77 [0.48, 1.25]
2 studies · 667 participants
Low

Number of participants with any adverse event (primary tolerability outcome) · Adults (aged 18 and over) with acute mania

The review found no eligible studies for this question.

1 finding from 1 review

Valproate for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adverse effects: 1. Sedation · Adults (aged 18 and over) with acute mania

Valproate leads to lower adverse events ‐ Sedation At 3‐12 weeks (secondary tolerability… compared with olanzapine (high certainty).

1 finding from 1 review

Valproate for acute mania 2019 · Cochrane Headline outcomes only
OR 0.5 [0.28, 0.91]
2 studies · 536 participants
High

Change in symptom severity at 3 weeks (secondary efficacy outcome) · Adults (aged 18 and over) with acute mania

1 finding from 1 review

Valproate for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 826 participants
High

Dropout · Adults (aged 18 and over) with acute mania

Valproate showed no clear difference in dropout rate ‐ All‐cause At 3‐12 weeks (secondary acceptability… compared with olanzapine (high certainty).

1 finding from 1 review

Valproate for acute mania 2019 · Cochrane Headline outcomes only
OR 1.04 [0.71, 1.52]
3 studies · 616 participants
High